Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

AbstractImmune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolumab retreatment remains unresolved. In this retrospective study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab in complete response (CR), the possibility of durable remission achievement (2-year PFS was 55.1%) was demonstrated. Retreatment with nivolumab has demonstrated efficacy with high overall response rate (ORR) and CR (67% and 33.3% respectively). At the final analysis, all patients were alive with median PFS of 16.5 months. Grade 3 –4 adverse events (AEs) were reported in 36% of patients, and there was no deterioration in terms of nivolumab retreatment–associated complications.

Source: Annals of Hematology - February 2, 2021 Category: Hematology Source Type: research